// App-Quantinova.ai

10418 : Efficacy and Safety of Rivaroxaban Compared with Warfarin Among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET-AF Trial

Researchers

Presenter

  • Graeme J Hankey

Principal Investigators

  • Daniel Wojdyla

  • Christopher C Nessel

  • Kenneth W Mahaffey

  • Robert M Califf

  • Keith A Fox

  • Jonathan P Piccini

  • Yuliya Lokhnygina

  • Manesh R Patel

  • Gunter Breithardt

  • Daniel E Singer

  • Richard C Becker

  • Werner Hacke

  • John F Paolini

Medical Centers

  • Duke Clinical Res Inst, Duke Univ Medical Ctr, Durham, NC

  • University Hospital of Muenster, Muenster, Germany

  • Univ of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

  • Mount Sinai School of Medicine, New York, NY

  • Duke Translational Med Inst, Duke Univ Sch of Med, Durham, NC

  • Massachusetts General Hosp Harvard Medcl School, Boston, MA

  • Royal Perth Hospital, Perth, WA, Australia

  • Ruprecht Karls University Heidelberg, Mannheim, Germany

Locations

  • United States

  • Germany

  • United Kingdom

  • Australia

Companies

  • Johnson & Johnson Se

  • Bayer

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Non-valvular atrial fibrillation

  • Ischemic stroke

  • Venous thrombosis

  • Stroke

Biomarkers

  • Creatinine

Drug/Treatment

  • rivaroxaban

  • Warfarin

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved